Abstract: The invention relates to methods and reagents for producing DNA vectors, in particular minicircle (MC) DNA vectors, in superhelical form. The invention further relates to highly pure preparations of circular DNA vectors, in particular MC DNA vectors.

Abstract: The present invention relates to liquid formulations of human interferon-?. The formulations are characterized in that they have a buffer with a pH in the weakly acidic to neutral range of between 5 and 8, preferably between over 5.5 and 8, and that they exhibit high stability of the interferon-? in solution while retaining the molecular integrity.

Abstract: The present invention relates to liquid formulations of human interferon-?. The formulations are characterized in that they have a buffer with a pH in the weakly acidic to neutral range of between 5 and 8, preferably between over 5.5 and 8, and that they exhibit high stability of the interferon-? in solution while retaining the molecular integrity.

Abstract: The present invention relates to liquid formulations of human interferon-?. The formulations are characterized in that they have a buffer with a pH in the weakly acidic to neutral range of between 5 and 8, preferably between over 5.5 and 8, and that they exhibit high stability of the interferon-? in solution while retaining the molecular integrity.

Abstract: The present invention is based on the observation that HIV does not only interact with the CD4 receptor of target cells but that there exists a different type of interaction between HIV envelope protein and the IFN receptor of the target cell. Thus, blocking such interaction can be useful for preventing or treating retroviral infections. Accordingly, the present invention relates to pharmaceutical compositions for competitively inhibiting the binding of a retrovirus, preferably HIV, to the IFN-receptor of a target cell. Preferably, said pharmaceutical compositions comprise a protein, polypeptide or equivalent molecule or a combination thereof which binds to the IFN-.alpha./.beta.-receptor or to HIV-gp41. Furthermore, the present invention relates to the use of said protein, polypeptide or equivalent molecule or IFN-.beta. or a combination thereof for the preparation of a pharmaceutical composition for preventing or treating retroviral infections.